Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI363 in Advanced Solid Tumors or Lymphoma
NCT05460767Phase 1Active, not recruiting
- Sponsor
- Innovent Biologics
- Start
- Aug 2022
- Primary completion
- Dec 2026
- Modality
- Bispecific Antibodies, Antibody-Drug Conjugates (ADCs), Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of IBI363 in solid tumor and lymphoma (2 arms), sponsored by Innovent Biologics. Primary endpoints: Dose-Limiting Toxicity at 21 days, Adverse Events at 90 days and 5 more. Started Aug 2022; status: active, not recruiting.
02
Drugs
IBI363
03
Conditions
solid tumorlymphoma
Beyond the preview
Go deeper on NCT05460767.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05460767.